Active surveillance (AS) is an observation strategy for patients with low-risk papillary thyroid microcarcinoma (PTMC) — tumors ≤1 cm confined to the thyroid with no high-risk features. Rather than proceeding directly to surgery, patients are monitored with periodic ultrasound and clinical evaluation. Surgery is reserved for tumors that grow or develop concerning features. Dr. Guttler has followed this approach for selected patients for decades, long before it became mainstream in American guidelines.
Patient Story
Patricia, 58
Patricia was referred to me after a neck ultrasound incidentally found a 6mm thyroid nodule. Fine-needle aspiration confirmed papillary thyroid microcarcinoma. Her surgeon recommended immediate thyroidectomy. Patricia was understandably frightened — but she was also on blood thinners for a heart condition, making surgery risky. I reviewed her ultrasound carefully: the tumor was well away from the trachea and recurrent laryngeal nerve, with no lymph node involvement. I offered active surveillance. Over four years of twice-yearly ultrasounds, her tumor has not grown by a single millimeter. She has avoided surgery entirely. 'I was terrified when I heard the word cancer,' she told me. 'Now I understand that watching carefully is the right treatment for my situation.'
What Is Active Surveillance?
Active surveillance is a structured monitoring program — not neglect. Patients undergo thyroid ultrasound every 6 months for the first 2 years, then annually if stable. Clinical examination and thyroid function tests are performed at each visit. The key distinction from 'watchful waiting' is that AS has defined criteria for intervention: if the tumor grows by ≥3 mm, develops new high-risk ultrasound features, or lymph node metastases appear, surgery is promptly recommended. Studies from Japan, where AS has been practiced since the 1990s, show that fewer than 5% of patients on AS ultimately require surgery within 10 years.
Who Is a Candidate?
Active surveillance is appropriate for patients with papillary thyroid microcarcinoma (≤1 cm) that meets all of the following low-risk criteria: no extrathyroidal extension (tumor confined within the thyroid capsule), no lymph node or distant metastases on imaging, no high-risk ultrasound features (irregular margins, microcalcifications, taller-than-wide shape), tumor location away from the trachea and recurrent laryngeal nerve, and no aggressive histologic variants (tall cell, columnar cell, hobnail). AS is also appropriate for older patients, those with significant surgical comorbidities, and patients who strongly prefer to avoid surgery after thorough counseling. It is NOT appropriate for tumors >1 cm, tumors abutting the trachea or recurrent laryngeal nerve, or any high-risk features.
The Evidence: What Studies Show
The evidence base for active surveillance in low-risk PTMC is now robust. The landmark Kuma Hospital study (Ito et al.) followed over 1,800 patients on AS for up to 20 years. Only 3.8% showed tumor enlargement ≥3 mm at 10 years; only 1.7% developed lymph node metastases. Disease-specific survival was 100%. A 2025 JAMA Surgery study by Saw et al. (160:1117–1124) analyzed outcomes in 222 patients on AS vs. immediate surgery and confirmed that AS is safe, with no disease-specific deaths and no cases of distant metastasis in the surveillance group. Crucially, the patients who eventually required surgery after a period of AS had outcomes equivalent to those who had immediate surgery — demonstrating that a brief period of observation does not compromise the cure rate.
Active Surveillance vs. Immediate Surgery
The risks of thyroid surgery — even in expert hands — are real: permanent hypoparathyroidism (low calcium) occurs in 1–3% of patients, permanent recurrent laryngeal nerve injury (voice change) in 1–2%, and lifelong levothyroxine dependence after total thyroidectomy. For a 6mm tumor that has a 95% chance of never growing or spreading, these surgical risks must be weighed carefully. Active surveillance eliminates surgical risk entirely for the majority of patients who will never need an operation. For the minority who do progress, surgery remains equally effective. The American Thyroid Association (ATA) 2015 guidelines and the 2023 ATA update both endorse AS as an acceptable management option for low-risk PTMC in appropriate patients.
The Psychological Dimension
Living with a known cancer diagnosis — even a tiny, low-risk one — is psychologically challenging. Some patients cannot tolerate the uncertainty of surveillance and prefer definitive surgical treatment. This is a completely valid choice, and I respect it. My role is to ensure patients make an informed decision: understanding both the very low risk of AS and the real (if small) risks of surgery. Studies show that with proper counseling, the majority of patients offered AS choose it and report high satisfaction and quality of life. The key is a physician who takes the time to explain the evidence, answer questions honestly, and provide the reassurance that comes from regular, expert monitoring.
Dr. Guttler's Approach
I have offered active surveillance to appropriate patients for many years — before it became standard in American guidelines. My approach: thorough initial evaluation including high-resolution ultrasound and review of all biopsy material; clear explanation of the evidence and the monitoring protocol; shared decision-making that respects the patient's values and preferences; and meticulous follow-up with ultrasound every 6 months for 2 years, then annually. I maintain a low threshold for recommending surgery if any concerning change appears. For patients who are good candidates, AS offers the possibility of avoiding surgery — and all its risks — entirely. That is a meaningful benefit that every eligible patient deserves to know about.
